Telimisartan has been shown to downregulate Bcl-2, previously associated with VEGF induction, in lung cancer cells [47, 72], whereas losartan was found to inhibit Ang II-induced VEGFA and IL-8 expression in liver cancer [73]. The gene discussed is VEGFA; the disease is lung carcinoma.